{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:32:39Z","timestamp":1785148359881,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The development of novel treatment options and the implementation of newborn screening programs have significantly transformed the landscape of care for patients with spinal muscular atrophy (SMA). In a relatively short span, SMA has evolved from a debilitating and fatal disorder into a treatable condition, primarily due to advancements in gene-targeted therapies. Onasemnogene abeparvovec-xioi, an adeno-associated viral vector-based gene therapy delivering a functional copy of the SMN1 gene, has shown significant efficacy in improving motor function and survival rates. In Croatia, this therapy has been integrated into routine clinical practice for several years, providing valuable real-world data on its long-term outcomes and effectiveness. The presented case study aims to document these clinical experiences, contributing to the growing body of evidence supporting the efficacy and safety of onasemnogene abeparvovec-xioi and highlighting the crucial role of early diagnosis and intervention in SMA management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective case series analysis of five pediatric patients diagnosed with SMA type 1, treated with onasemnogene abeparvovec-xioi at a tertiary care center in Croatia. Four patients presented with hypotonia and motor developmental delay, and one was identified through newborn screening. All patients had genetically confirmed SMA, underwent CHOP-INTEND (Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders) testing pre- and post-treatment, and were monitored for clinical response and adverse events. In addition, a systematic literature search was conducted using PubMed and Scopus databases to identify reports of pediatric SMA type 1 patients treated with onasemnogene abeparvovec. Keywords used included \u201conasemnogene abeparvovec\u201d and \u201cspinal muscular atrophy.\u201d A total of 33 articles, describing 408 pediatric patients, were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>We describe a series of five patients, four of which initially presented with varying degrees of hypotonia and delay in motor development, while one patient was discovered through newborn screening program. All patients received genetic confirmation of SMA, underwent Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) testing and received onasemnogene abeparvovec treatment. Four out of five patients achieved adequate clinical improvement as show by the increase in CHOP-INTEND score. One patient showed signs of regression and required additional care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the widespread use of novel treatment modalities that have drastically improved patient outcomes, there remains a paucity of real-world case reports documenting the care of SMA patients. This case series and accompanying literature review reinforce the efficacy and safety of onasemnogene abeparvovec in the treatment of SMA type 1, particularly when initiated early. In addition, our case series emphasize the critical role of newborn screening in identifying affected individuals before the onset of irreversible motor neuron loss as well as prompt start of treatment in all patients. We hope that our findings will contribute meaningfully to the expanding body of literature and knowledge on spinal muscular atrophy, ultimately fostering better patient care and outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1609072","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:21:44Z","timestamp":1750742504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world outcomes of spinal muscular atrophy treatment with onasemnogene abeparvovec in Croatia: a comprehensive case series and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Ivan","family":"Lehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Mato\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovro","family":"Lamot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Bunoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.spen.2021.100878","article-title":"Spinal muscular atrophy","volume":"37","author":"Nicolau","year":"2021","journal-title":"Semin Pediatr Neurol"},{"key":"ref3","first-page":"591","article-title":"Spinal muscular atrophy","volume-title":"Handbook of clinical neurology","author":"Arnold","year":"2018"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal muscular atrophy: mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl Clin Genet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene Abeparvovec: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2023.1230889","article-title":"Case report: a case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment","volume":"14","author":"Nigro","year":"2023","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acn3.52018","article-title":"Early spinal muscular atrophy treatment following newborn screening: a 20-month review of the first Italian regional experience","volume":"11","author":"Gagliardi","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1542\/PEDS.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies","volume":"59","author":"Pane","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","article-title":"Gene therapy for spinal muscular atrophy: the Qatari experience","volume":"28","author":"Ali","year":"2021","journal-title":"Gene Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/j.spen.2021.100899","article-title":"Spinal muscular atrophy treatments, newborn screening, and the creation of a Neurogenetics urgency","volume":"38","author":"Butterfield","year":"2021","journal-title":"Semin Pediatr Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn screening\u2014a","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Systematic Rev Genes"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with Onasemnogene Abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2739\/kurumemedj.MS6934008","article-title":"Onasemnogene Abeparvovec treatment after Nusinersen in an infant with spinal muscular atrophy type 1","volume":"69","author":"Nanri","year":"2024","journal-title":"Kurume Med J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mus.27375","article-title":"Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1","volume":"64","author":"Oechsel","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1007\/s00415-024-12318-z","article-title":"JEWELFISH: 24-month results from an open-label study in non-treatment-na\u00efve patients with SMA receiving treatment with risdiplam","volume":"271","author":"Chiriboga","year":"2024","journal-title":"J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.pedneo.2022.07.006","article-title":"Crowdfunding approach for gene therapy: experience from the UAE","volume":"63","author":"Elbashir","year":"2022","journal-title":"Pediatr Neonatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41434-023-00401-5","article-title":"Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings","volume":"30","author":"Chand","year":"2023","journal-title":"Gene Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1212\/WNL.0000000000201294","article-title":"Bridging the gap: gene therapy in a patient with spinal muscular atrophy type 1","volume":"99","author":"Costamagna","year":"2022","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12883-023-03420-2","article-title":"Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports","volume":"23","author":"Mizuno","year":"2023","journal-title":"BMC Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1212\/WNL.0000000000200676","article-title":"Child neurology: pathologically confirmed thrombotic Microangiopathy caused by Onasemnogene Abeparvovec treatment for SMA","volume":"98","author":"Yazaki","year":"2022","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.01.012","article-title":"Clinical experience with gene therapy in older patients with spinal muscular atrophy","volume":"118","author":"Matesanz","year":"2021","journal-title":"Pediatr Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.lanepe.2023.100817","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg Health - Eur"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.17650\/2222-8721-2022-12-1-29-38","article-title":"Experience of using gene replacement therapy with Zolgensma\u00ae (onasemnogene abeparvovec) in real clinical practice in Russia","volume":"12","author":"Artemyeva","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"100973","DOI":"10.1016\/j.ymgmr.2023.100973","article-title":"Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth","volume":"35","author":"Sawada","year":"2023","journal-title":"Mol Genet Metab Rep"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","article-title":"Implications of circulating neurofilamentsfor spinal muscular atrophytreatment early in life: a case series","volume":"23","author":"Alves","year":"2021","journal-title":"Mol Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.15690\/vsp.v21i6S.2497","article-title":"Interim analysis of treatment outcomes of young children with 5q spinal muscular atrophy on gene replacement therapy with onasemnogene abeparvovec. Clinical observations","volume":"21","author":"Kokorina","year":"2022","journal-title":"Vopr Sovrem Pediatr - Curr Pediatr"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.11251\/ojjscn.55.443","article-title":"Two cases of spinal muscular atrophy type I that received early treatment and achieved improved prognosis by promoting multi-center, multi-professional collaboration after prenatal diagnosis","volume":"55","author":"Kato","year":"2023","journal-title":"No To Hattatsu"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijns7020026","article-title":"Massachusetts\u2019 findings from statewide newborn screening for spinal muscular atrophy","volume":"7","author":"Hale","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2024.1326528","article-title":"Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of SMN2 before and after treatment: a longitudinal observational study","volume":"15","author":"Bitetti","year":"2024","journal-title":"Front Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"262","DOI":"10.11251\/ojjscn.54.262","article-title":"Treatment of a 50-day-old Japanese infant with spinal muscular atrophy type 1 using onasemnogene abeparvovec","volume":"54","author":"Nambu","year":"2022","journal-title":"No To Hattatsu"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/children11050590","article-title":"Onasemnogene abeparvovec administration via peripherally inserted central catheter: a case report","volume":"11","author":"Pitarch Castellano","year":"2024","journal-title":"Children (Basel)"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D\u2019Silva","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/00185787231182562","article-title":"Onasemnogene Abeparvovec: post-infusion efficacy and safety in patients with spinal muscular atrophy (SMA)\u2014a Fondazione Policlinico Gemelli IRCCS experience","volume":"59","author":"Favia","year":"2024","journal-title":"Hosp Pharm"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1007\/s12325-023-02685-w","article-title":"Patient and caregiver outcomes after Onasemnogene Abeparvovec treatment: findings from the Cure SMA 2021 membership survey","volume":"40","author":"Toro","year":"2023","journal-title":"Adv Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36185\/2532-1900-356","article-title":"Sequential treatment with nusinersen, Zolgensma\u00ae and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report","volume":"42","author":"Bitetti","year":"2023","journal-title":"Acta Myol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.11604\/pamj.2023.46.78.32240","article-title":"Spinal muscular atrophy in Ghanaian children confirmed by molecular genetic testing: a case series","volume":"46","author":"Hammond","year":"2023","journal-title":"Pan Afr Med J"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.36185\/2532-1900-077","article-title":"Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam","volume":"41","author":"Tosi","year":"2022","journal-title":"Acta Myol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mus.27261","article-title":"Time is muscle: a recommendation for early treatment for preterm infants with spinal muscular atrophy","volume":"64","author":"Lee","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study","volume":"23","author":"Stettner","year":"2023","journal-title":"BMC Neurol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1609072\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:21:47Z","timestamp":1750742507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1609072\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":51,"alternative-id":["10.3389\/fmed.2025.1609072"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1609072","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"article-number":"1609072"}}